JP2022523552A5 - - Google Patents

Info

Publication number
JP2022523552A5
JP2022523552A5 JP2021552598A JP2021552598A JP2022523552A5 JP 2022523552 A5 JP2022523552 A5 JP 2022523552A5 JP 2021552598 A JP2021552598 A JP 2021552598A JP 2021552598 A JP2021552598 A JP 2021552598A JP 2022523552 A5 JP2022523552 A5 JP 2022523552A5
Authority
JP
Japan
Prior art keywords
amino acid
eso
tcr
acid sequence
constant region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523552A (ja
JP7748874B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/051807 external-priority patent/WO2020178738A1/en
Publication of JP2022523552A publication Critical patent/JP2022523552A/ja
Publication of JP2022523552A5 publication Critical patent/JP2022523552A5/ja
Application granted granted Critical
Publication of JP7748874B2 publication Critical patent/JP7748874B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552598A 2019-03-04 2020-03-03 Ｔ細胞受容体及びその使用方法 Active JP7748874B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813639P 2019-03-04 2019-03-04
US62/813,639 2019-03-04
PCT/IB2020/051807 WO2020178738A1 (en) 2019-03-04 2020-03-03 T cell receptors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022523552A JP2022523552A (ja) 2022-04-25
JP2022523552A5 true JP2022523552A5 (enExample) 2023-03-13
JP7748874B2 JP7748874B2 (ja) 2025-10-03

Family

ID=72336933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552598A Active JP7748874B2 (ja) 2019-03-04 2020-03-03 Ｔ細胞受容体及びその使用方法

Country Status (13)

Country Link
US (1) US20220169695A1 (enExample)
EP (1) EP3935173A4 (enExample)
JP (1) JP7748874B2 (enExample)
KR (1) KR20210149051A (enExample)
CN (1) CN113853434B (enExample)
AU (1) AU2020231106A1 (enExample)
BR (1) BR112021017486A2 (enExample)
CA (1) CA3132252A1 (enExample)
IL (1) IL286032A (enExample)
MX (1) MX2021010533A (enExample)
SG (1) SG11202109588RA (enExample)
TW (1) TWI875737B (enExample)
WO (1) WO2020178738A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021010537A (es) 2019-03-04 2021-12-10 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
AU2020231927A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
US12522644B2 (en) 2019-03-04 2026-01-13 University Health Network T cell receptors and methods of use thereof
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
CA3133945A1 (en) 2019-03-25 2020-10-01 University Health Network T cell receptors and methods of use thereof
WO2022099543A1 (zh) * 2020-11-12 2022-05-19 深圳先进技术研究院 Ny-eso-1基因抑制剂作为抗肿瘤化疗药物增敏剂的应用
US20240327492A1 (en) * 2021-07-29 2024-10-03 Nantcell, Inc. Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer
CN117843800B (zh) * 2023-12-01 2026-07-24 浙江大学 一种靶向胞内ny-eso-1的双特异抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506875B1 (en) * 2000-09-26 2003-01-14 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-C molecules and uses thereof
US20100068142A1 (en) * 2006-10-03 2010-03-18 Craig Gedye Melanoma repopulating cells
US8105831B2 (en) * 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
EP3031916B1 (en) * 2007-06-11 2017-06-07 Takara Bio Inc. Method for expression of specific gene
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
DK2971045T3 (da) * 2013-03-13 2019-09-16 Health Research Inc Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen
CA2964785A1 (en) * 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
JP6895975B2 (ja) * 2016-01-06 2021-06-30 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 組換えｔ細胞受容体を含む組成物及びライブラリー並びに組換えｔ細胞受容体を使用する方法
WO2017152042A2 (en) * 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity

Similar Documents

Publication Publication Date Title
JP2022527267A5 (enExample)
JP2022524993A5 (enExample)
JP2022523554A5 (enExample)
JP2022524994A5 (enExample)
JP2022523971A5 (enExample)
JP2022523553A5 (enExample)
JP2022524992A5 (enExample)
Baxevanis et al. Cancer immunotherapy
JP2022543059A5 (enExample)
Shilyansky et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
EP2446897A1 (en) Anti-KIR combination treatments and methods
Tsang et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
AU2025203036A1 (en) NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
US20170232070A1 (en) Combination Methods for Immunotherapy
Junghans The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
US11951131B2 (en) Anti-SLAMF7 chimeric antigen receptors
CN108138148A (zh) T细胞的激活和扩增
CN113795583B (zh) T细胞受体及其使用方法
JP2022543060A5 (enExample)
JP2022543058A5 (enExample)
CA3052803A1 (en) Maximizing t-cell memory and compositions and methods therefor
JP2020533962A5 (enExample)
AU2020231694A1 (en) T cell receptors and methods of use thereof
JP2023542528A5 (enExample)
JP2023521219A5 (enExample)